(Sivumennen sanoen: olenn pohtinut mistähän molekyylistä COVID ottaa jakson PRRA.
löydän nyt yhden ja se on interferonista
joka on joillain maailman ihmisilla myös koronavirusta vastaan antiviraali.
Kaikilla maailman tätä IFNlamda4 inerferonia ei muodostu.
ORIGIN 1 mrpsvwaava aglwvlctvi aaaprrclls hyrsleprtl aaakalrdry eeealswgqr 61 ncsfrprrdp prpsscarlr hvargiadaq avlsglhrse llpgagpile llaaagrdva 121 aclelarpgs srkvpgaqkr rhkprradsp rcrkasvvfn llrlltwelr laahsgpcl
COVID on ottanut insertion - PRRA- tuohon kohtaan missä se tekee biosynteesinä S1/S2 pilkkoutuman Siinä on tullainen juuri insertio. -prra- sivumennen sanoen, jonka kaltainen löytyy intereronista joka voisi tunnistaa tuon viruksen. Sattumalöytö vain. Muistiin)
Abstract
The recently discovered IFN‐λ4 has been found to have
antiviral activity against several viruses. However, it's unknown
whether IFN‐λ4 can inhibit HIV infection. Here, we show that IFN‐λ4
could suppress HIV infection of macrophages. This IFN‐λ4‐mediated HIV
inhibition was compromised by the antibodies against IFN‐λ receptor
complex, IFN‐λR1/IL‐10R2. IFN‐λ4 enhanced the phosphorylation of STAT1,
and induced antiviral interferon‐stimulated genes. These findings
indicated that IFN‐λ4 can inhibit HIV via JAK/STAT signalling pathway.
..
IFNL4 genome contains a dinucleotide variant, IFNL4‐ΔG/TT (rs368234815, originally designated as ss469415590) in exon 1 of IFNL4, upstream of IFN‐λ3 on chromosome 19q13.13. The IFNL4‐ΔG allele generates a functional IFN‐λ4 protein p179 (179 aa) by introducing a frameshift mutation that enables transcription, and the homozygous TT genotype creates a premature stop codon and thus knockouts this gene. IFN‐λ4 expresses in a small fraction of Asian and about half of European populations, but in most of Africans.4 Genetic studies have demonstrated that IFNL4‐TT allele has a strong positive correlation with HCV clearance, treatment outcome of HCV infection, and innate resistance to HIV infection, on the contrary, IFNL4‐ΔG allele is associated with the impairment of HCV clearance, and unfavourable clinical and immunological status in HIV/HCV co‐infected subjects.4-6 But there was also evidence supported that IFNL4 genotype is not associated with the antiviral interferon‐stimulated genes (ISGs) expression and HIV load in chronic HIV infection.7
..
IFNL4 genome contains a dinucleotide variant, IFNL4‐ΔG/TT (rs368234815, originally designated as ss469415590) in exon 1 of IFNL4, upstream of IFN‐λ3 on chromosome 19q13.13. The IFNL4‐ΔG allele generates a functional IFN‐λ4 protein p179 (179 aa) by introducing a frameshift mutation that enables transcription, and the homozygous TT genotype creates a premature stop codon and thus knockouts this gene. IFN‐λ4 expresses in a small fraction of Asian and about half of European populations, but in most of Africans.4 Genetic studies have demonstrated that IFNL4‐TT allele has a strong positive correlation with HCV clearance, treatment outcome of HCV infection, and innate resistance to HIV infection, on the contrary, IFNL4‐ΔG allele is associated with the impairment of HCV clearance, and unfavourable clinical and immunological status in HIV/HCV co‐infected subjects.4-6 But there was also evidence supported that IFNL4 genotype is not associated with the antiviral interferon‐stimulated genes (ISGs) expression and HIV load in chronic HIV infection.7
Inga kommentarer:
Skicka en kommentar